Seven Years Follow-Up of Biodegradable Polymer Coated Paclitaxel-Eluting Infinnium Coronary Stent in Saudi Arabia


Aim: In the present study, we analyzed 7-year clinical outcomes of patients included in the BIO degradable Polymer coated drug-eluting stent REgistry of Sahajanand Medical Technologies Pvt. Ltd. stents in Saudi Arabia (BIOPRESS)-Infinnium? registry. Methods: This was multicentre, observational, non-randomized, post-marketing surveillance registry, which included 276 consecutive patients treated with Infinnium? paclitaxel-eluting stent between July-2004 and June-2006. All patients underwent single-vessel or multiple-vessel percutaneous coronary intervention with high atherosclerotic risk factors and the patients were followed up to 7 years. Baseline and post-procedure angiographic follow-up were pre-specified in 231 patients. Results: The registry included 276 consecutive patients (81.5% male) with a mean age of 56.0 ± 11.1 years. Among 276 patients, diabetes and hypertension were present in 142 (51.4%) and 172 (62.3%) of patients respectively. Of all patients studied, 186 (67.4%) had single-vessel disease, 75 (27.2%) had double-vessel disease, and 15 (5.4%) had triple-vessel disease. Total 476 Infinnium? stents were implanted with an average stent length of 21.8 ± 7.5 mm. The incidence of major adverse cardiac events (MACE) up to 1 year was 26 (9.4%). Clinical follow-up was completed in 235 patients at seven-year follow-up. The data of seven-year clinical outcomes were as follow: cumulative MACE rate of 18.1% with 7.6% of total mortality and 3.6% of restenosis. Conclusion: These 7-year results of BIOPRESS-Infinnium? registry clearly provide evidence for safety and long-term effectiveness of the Infinnium? paclitaxel-eluting stent with the biodegradable polymer in real-life patients.

Share and Cite:

Mimish, L. , Khoja, A. , Anwar, M. , Rizniceck, V. , Hasan, T. and Thakkar, A. (2014) Seven Years Follow-Up of Biodegradable Polymer Coated Paclitaxel-Eluting Infinnium Coronary Stent in Saudi Arabia. International Journal of Clinical Medicine, 5, 216-224. doi: 10.4236/ijcm.2014.55035.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Holmes, D.R., Leon, M.B., Moses, J.W., Popma, J.J., Cutlip, D., Fitzgerald, P.J., Brown, C., Fischell, T., Wong, S.C. and Midei, M. (2004) Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial a Randomized Trial of a Sirolimus-Eluting Stent versus a Standard Stent in Patients at High Risk for Coronary Restenosis. Circulation, 109, 634-640.
[2] Kastrati, A., Mehilli, J., Pache, J., Kaiser, C., Valgimigli, M., Kelbæk, H., Menichelli, M., Sabaté, M., Suttorp, M.J. and Baumgart, D. (2007) Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. New England Journal of Medicine, 356, 1030-1039.
[3] Fajadet, J., Wijns, W., Laarman, G.-J., Kuck, K.-H., Ormiston, J., Münzel, T., Popma, J.J., Fitzgerald, P.J., Bonan, R. and Kuntz, R.E. (2006) Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions Clinical and Angiographic Results of the Endeavor II Trial. Circulation, 114, 798-806.
[4] Stone, G.W., Moses, J.W., Ellis, S.G., Schofer, J., Dawkins, K.D., Morice, M.-C., Colombo, A., Schampaert, E., Grube, E. and Kirtane, A.J. (2007) Safety and Efficacy of Sirolimus and Paclitaxel-Eluting Coronary Stents. New England Journal of Medicine, 356, 998-1008.
[5] Kastrati, A., Dibra, A., Spaulding, C., Laarman, G.J., Menichelli, M., Valgimigli, M., Di Lorenzo, E., Kaiser, C., Tierala, I. and Mehilli, J. (2007) Meta-Analysis of Randomized Trials on Drug-Eluting Stents vs. Bare-Metal Stents in Patients with Acute Myocardial Infarction. European Heart Journal, 28, 2706-2713.
[6] Wenaweser, P., Daemen, J., Zwahlen, M., van Domburg, R., Jüni, P., Vaina, S., Hellige, G., Tsuchida, K., Morger, C. and Boersma, E. (2008) Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice 4-Year Results from a Large 2-Institutional Cohort Study. Journal of the American College of Cardiology, 52, 1134-1140.
[7] Spaulding, C., Daemen, J., Boersma, E., Cutlip, D.E. and Serruys, P.W. (2007) A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. New England Journal of Medicine, 356, 989-997.
[8] Cook, S., Ladich, E., Nakazawa, G., Eshtehardi, P., Neidhart, M., Vogel, R., Togni, M., Wenaweser, P., Billinger, M. and Seiler, C. (2009) Correlation of Intravascular Ultrasound Findings with Histopathological Analysis of Thrombus Aspirates in Patients with Very Late Drug-Eluting Stent Thrombosis. Circulation, 120, 391-399.
[9] Joner, M., Finn, A.V., Farb, A., Mont, E.K., Kolodgie, F.D., Ladich, E., Kutys, R., Skorija, K., Gold, H.K. and Virmani, R. (2006) Pathology of Drug-Eluting Stents in Humans Delayed Healing and Late Thrombotic Risk. Journal of the American College of Cardiology, 48, 193-202.
[10] Wilson, G.J., Nakazawa, G., Schwartz, R.S., Huibregtse, B., Poff, B., Herbst, T.J., Baim, D.S. and Virmani, R. (2009) Comparison of Inflammatory Response after Implantation of Sirolimus and Paclitaxel-Eluting Stents in Porcine Coronary Arteries. Circulation, 120, 141-149.
[11] Carter, A.J., Aggarwal, M., Kopia, G.A., Tio, F., Tsao, P.S., Kolata, R., Yeung, A.C., Llanos, G., Dooley, J. and Falotico, R. (2004) Long-Term Effects of Polymer-Based, Slow-Release, Sirolimus-Eluting Stents in a Porcine Coronary Model. Cardiovascular Research, 63, 617-624.
[12] Vranckx, P., Serruys, P., Gambhir, S., Sousa, E., Abizaid, A., Lemos, P., Ribeiro, E., Dani, S., Dalal, J. and Mehan, V. (2006) Biodegradable-Polymer-Based, Paclitaxel-Eluting InfinniumTMStent: 9-Month Clinical and Angiographic Follow-Up Results from the SIMPLE II Prospective Multi-Centre Registry Study. EuroIntervention, 2, 310-317.
[13] Cutlip, D.E., Windecker, S., Mehran, R., Boam, A., Cohen, D.J., van Es, G.-A., Steg, P.G., Morel, M.-A., Mauri, L. and Vranckx, P. (2007) Clinical End Points in Coronary Stent Trials a Case for Standardized Definitions. Circulation, 115, 2344-2351.
[14] Dibra, A., Kastrati, A., Alfonso, F., Seyfarth, M., Pérez-Vizcayno, M.-J., Mehilli, J. and Schömig, A. (2007) Effectiveness of Drug-Eluting Stents in Patients with Bare-Metal In-Stent RestenosisMeta-Analysis of Randomized Trials. Journal of the American College of Cardiology, 49, 616-623.
[15] Win, H.K., Caldera, A.E., Maresh, K., Lopez, J., Rihal, C.S., Parikh, M.A., Granada, J.F., Marulkar, S., Nassif, D. and Cohen, D.J. (2007) Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents. JAMA: The Journal of the American Medical Association, 297, 2001-2009.
[16] Beohar, N., Davidson, C.J., Kip, K.E., Goodreau, L., Vlachos, H.A., Meyers, S.N., Benzuly, K.H., Flaherty, J.D., Ricciardi, M.J. and Bennett, C.L. (2007) Outcomes and Complications Associated with Off-Label and Untested Use of Drug-Eluting Stents. JAMA: The Journal of the American Medical Association, 297, 1992-2000.
[17] Marroquin, O.C., Selzer, F., Mulukutla, S.R., Williams, D.O., Vlachos, H.A., Wilensky, R.L., Tanguay, J.-F., Holper, E.M., Abbott, J.D. and Lee, J.S. (2008) A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications. New England Journal of Medicine, 358, 342-352.
[18] Finn, A.V., Joner, M., Nakazawa, G., Kolodgie, F., Newell, J., John, M.C., Gold, H.K. and Virmani, R. (2007) Pathological Correlates of Late Drug-Eluting Stent Thrombosis Strut Coverage as a Marker of Endothelialization. Circulation, 115, 2435-2441.
[19] Finn, A.V., Nakazawa, G., Joner, M., Kolodgie, F.D., Mont, E.K., Gold, H.K. and Virmani, R. (2007) Vascular Responses to Drug Eluting Stents Importance of Delayed Healing. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1500-1510.
[20] Colombo, A., Drzewiecki, J., Banning, A., Grube, E., Hauptmann, K., Silber, S., Dudek, D., Fort, S., Schiele, F., Zmudka, K., Guagliumi, G. and Russell, M.E. (2003) Randomized Study to Assess the Effectiveness of Slow and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions. Circulation, 108, 788-794.
[21] Stone, G.W., Ellis, S.G., Cox, D.A., Hermiller, J., O’Shaughnessy, C., Mann, J.T., Turco, M., Caputo, R., Bergin, P. and Greenberg, J. (2004) A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. New England Journal of Medicine, 350, 221-231.
[22] Stone, G.W., Ellis, S.G., Cannon, L., Mann, J.T., Greenberg, J.D., Spriggs, D., O’Shaughnessy, C.D., DeMaio, S., Hall, P., Popma, J.J., Koglin, J. and Russell, M.E. (2005) Comparison of a Polymer-Based Paclitaxel-Eluting Stent with a Bare Metal Stent in Patients with Complex Coronary Artery Disease: A Randomized Controlled Trial. JAMA, 294, 1215-1223.
[23] Dawkins, K.D., Grube, E., Guagliumi, G., Banning, A.P., Zmudka, K., Colombo, A., Thuesen, L., Hauptman, K., Marco, J., Wijns, W., Popma, J.J., Koglin, J. and Russell, M.E. (2005) Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of complex, Long Coronary Artery Lesions from a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice. Circulation, 112, 3306-3313.
[24] Vedat, A., Selcuk, G., Refik, E., Onur, E., Murat, C., Burak, C., Murat, G. and Cemsid, D. (2009) Treatment of Patients with Coronary Artery Disease with Biodegradable Polymer Based Paclitaxel-Eluting Infinnium Coronary Stent System: Results of 1-Year Clinical Follow-Up a Single Center Experience. Indian Heart Journal, 61, 254.
[25] Ostovan, M.A., Mollazadeh, R., Kojuri, J. and Mirabadi, M. (2008) Experience with Paclitaxel-Eluting Infinnium Coronary Stents. Asian Cardiovascular and Thoracic Annals, 16, 454-458.
[26] Davlouros, P.A., Mavronasiou, E., Xanthopoulou, I., Karantalis, V., Tsigkas, G., Hahalis, G. and Alexopoulos, D. (2012) An Optical Coherence Tomography Study of Two New Generation Stents with Biodegradable Polymer Carrier, Eluting Paclitaxel vs. Biolimus-A9. International Journal of Cardiology, 157, 341-346.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.